Colin Dunstan

List of Publications by Year
in descending order

184	37,049	11651 70	3732 179
papers	citations	h-index	g-index

196	196	196	20652
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation. Cell, 1998, 93, 165-176.	28.9	4,946
2	Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density. Cell, 1997, 89, 309-319.	28.9	4,620
3	OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 1999, 397, 315-323.	27.8	3,093
4	osteoprotegerin-deficient mice develop early onset osteoporosis and arterialÂcalcification. Genes and Development, 1998, 12, 1260-1268.	5.9	2,176
5	Increased bone formation in osteocalcin-deficient mice. Nature, 1996, 382, 448-452.	27.8	1,522
6	Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3540-3545.	7.1	1,495
7	TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes and Development, 1999, 13, 1015-1024.	5.9	1,146
8	The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption. Journal of Bone and Mineral Research, 2000, 15, 2-12.	2.8	1,031
9	RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1566-1571.	7.1	1,004
10	Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1. Endocrinology, 1999, 140, 4382-4389.	2.8	690
11	A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women. Journal of Bone and Mineral Research, 2004, 19, 1059-1066.	2.8	657
12	The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts. Journal of Cell Biology, 1999, 145, 527-538.	5.2	634
13	Estrogen Stimulates Gene Expression and Protein Production of Osteoprotegerin in Human Osteoblastic Cells*. Endocrinology, 1999, 140, 4367-4370.	2.8	589
14	Interleukin-1Î² and tumor necrosis factor-Î±, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone, 1999, 25, 255-259.	2.9	575
15	Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis. Journal of Experimental Medicine, 2000, 192, 463-474.	8.5	494
16	The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women. Journal of Bone and Mineral Research, 2001, 16, 348-360.	2.8	418
17	Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11201-11206.	7.1	393
18	Osteoprotegerin Reduces Osteoclast Numbers and Prevents Bone Erosion in Collagen-Induced Arthritis. American Journal of Pathology, 2002, 161, 1419-1427.	3.8	352

#	Article	IF	Citations
19	A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer, 2003, 97, 887-892.	4.1	347
20	Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood, 2001, 98, 3534-3540.	1.4	344
21	Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis and Rheumatism, 2004, 50, 277-290.	6.7	297
22	Osteoprotegerin Production by Human Osteoblast Lineage Cells Is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and Cytokines. Biochemical and Biophysical Research Communications, 1998, 250, 776-781.	2.1	283
23	The incorporation of strontium and zinc into a calciumâ€“silicon ceramic for bone tissue engineering. Biomaterials, 2010, 31, 3175-3184.	11.4	261
24	Tumor necrosis factor Î±-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis and Rheumatism, 2002, 46, 785-792.	6.7	258
25	The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated**This work was supported by Grant AG-04875 from the National Institute on Aging.. Endocrinology, 2000, 141, 4768-4776.	2.8	255
26	Model structure and control of bone remodeling: A theoretical study. Bone, 2008, 43, 249-263.	2.9	237
27	Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Research, 2001, 61, 4432-6.	0.9	234
28	Bone Morphogenetic Protein 2 (BMP-2) Enhances BMP-3, BMP-4, and Bone Cell Differentiation Marker Gene Expression During the Induction of Mineralized Bone Matrix Formation in Culturesof Fetal Rat Calvarial Osteoblasts. Calcified Tissue International, 1997, 60, 283-290.	3.1	218
29	Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.. Journal of Clinical Investigation, 1997, 99, 2509-2517.	8.2	217
30	Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis. Endocrinology, 1999, 140, 4382-4389.	2.8	204
31	Effects of Immunosuppressants on Receptor Activator of NF-Î¹B Ligand and Osteoprotegerin Production by Human Osteoblastic and Coronary Artery Smooth Muscle Cells. Biochemical and Biophysical Research Communications, 2001, 280, 334-339.	2.1	196
32	Bone loss after liver transplantation. Hepatology, 1991, 14, 613-619.	7.3	182
33	Correlates of Osteoprotegerin Levels in Women and Men. Osteoporosis International, 2002, 13, 394-399.	3.1	177
34	A Chimeric Form of Osteoprotegerin Inhibits Hypercalcemia and Bone Resorption Induced by IL-1Î², TNF-Î±, PTH, PTHrP, and 1,25(OH)2D3. Journal of Bone and Mineral Research, 1999, 14, 1478-1485.	2.8	171
35	Effect of EstrogenversusTestosterone on Circulating Osteoprotegerin and Other Cytokine Levels in Normal Elderly Men. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1550-1554.	3.6	167
36	Estrogen Stimulates Gene Expression and Protein Production of Osteoprotegerin in Human Osteoblastic Cells. Endocrinology, 1999, 140, 4367-4370.	2.8	164

#	Article	IF	Citations
37	Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. Journal of Clinical Investigation, 2012, 122, 4172-4189.	8.2	163
38	The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis and Rheumatism, 2006, 54, 1772-1777.	6.7	158
39	Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin. Immunity, 2003, 19, 849-861.	14.3	149
40	Priming Adipose Stem Cells with Tumor Necrosis Factor-Alpha Preconditioning Potentiates Their Exosome Efficacy for Bone Regeneration. Tissue Engineering - Part A, 2017, 23, 1212-1220.	3.1	146
41	Osteoblasts Directly Control Lineage Commitment of Mesenchymal Progenitor Cells through Wnt Signaling. Journal of Biological Chemistry, 2008, 283, 1936-1945.	3.4	134
42	Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis and Rheumatism, 2003, 48, 2042-2051.	6.7	132
43	Vitamin D Deficiency Promotes Human Breast Cancer Growth in a Murine Model of Bone Metastasis. Cancer Research, 2010, 70, 1835-1844.	0.9	131
44	Recovery from Steroid-Induced Osteoporosis. Annals of Internal Medicine, 1987, 107, 319.	3.9	130
45	Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nature Clinical Practice Oncology, 2006, 3, 41-49.	4.3	128
46	E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Research, 1996, 56, 4063-70.	0.9	128
47	OPG and PTH-(1â€“34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats. Endocrinology, 2001, 142, 4295-4304.	2.8	121
48	The effects of cytokines and growth factors on osteoblastic cells. Bone, 1995, 17, S71-S75.	2.9	118
49	Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors. Journal of Cellular Biochemistry, 1999, 72, 251-261.	2.6	116
50	Characterization of osteoclast precursors in human blood. British Journal of Haematology, 2000, 111, 501-512.	2.5	112
51	Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nature Clinical Practice Oncology, 2007, 4, 42-55.	4.3	111
52	Systemic Administration of Acidic Fibroblast Growth Factor (FGF-1) Prevents Bone Loss and Increases New Bone Formation in Ovariectomized Rats. Journal of Bone and Mineral Research, 1999, 14, 953-959.	2.8	110
53	Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Research, 2000, 60, 783-7.	0.9	109
54	Markers of Bone Remodeling in Metastatic Bone Disease. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5059-5075.	3.6	106

#	Article	IF	Citations
55	Theoretical investigation of the role of the RANKâ€“RANKLâ€“OPG system in bone remodeling. Journal of Theoretical Biology, 2010, 262, 306-316.	1.7	102
56	Effect of aluminum on normal and uremic rats: Tissue distribution, vitamin D metabolites, and quantitative bone histology. Calcified Tissue International, 1983, 35, 344-351.	3.1	101
57	Repairing a critical-sized bone defect with highly porous modified and unmodified baghdadite scaffolds. Acta Biomaterialia, 2012, 8, 4162-4172.	8.3	101
58	Serum osteoprotegerin levels in healthy controls and cancer patients. Clinical Cancer Research, 2002, 8, 2306-10.	7.0	97
59	The Inhibition of RANKL Causes Greater Suppression of Bone Resorption and Hypercalcemia Compared with Bisphosphonates in Two Models of Humoral Hypercalcemia of Malignancy. Endocrinology, 2005, 146, 3235-3243.	2.8	95
60	Rationale for the role of osteoclastâ€like cells in arterial calcification. FASEB Journal, 2002, 16, 577-582.	0.5	94
61	Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in Rats. Journal of Bone and Mineral Research, 2003, 18, 852-858.	2.8	94
62	Adenoviral Delivery of Osteoprotegerin Ameliorates Bone Resorption in a Mouse Ovariectomy Model of Osteoporosis. Molecular Therapy, 2001, 3, 197-205.	8.2	93
63	Architectural Design of 3D Printed Scaffolds Controls the Volume and Functionality of Newly Formed Bone. Advanced Healthcare Materials, 2019, 8, e1801353.	7.6	89
64	Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clinical Cancer Research, 2001, 7, 2977-83.	7.0	87
65	Osteocyte death and hip fracture. Calcified Tissue International, 1993, 53, S113-S117.	3.1	83
66	Follicle-stimulating hormone increases bone mass in female mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 22629-22634.	7.1	83
67	Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone, 2007, 40, 471-478.	2.9	82
68	Glucocorticoid-dependent Wnt signaling by mature osteoblasts is a key regulator of cranial skeletal development in mice. Development (Cambridge), 2009, 136, 427-436.	2.5	82
69	Biphasic Glucocorticoid-Dependent Regulation of Wnt Expression and Its Inhibitors in Mature Osteoblastic Cells. Calcified Tissue International, 2009, 85, 538-545.	3.1	78
70	Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. Osteoporosis International, 2003, 14, 728-733.	3.1	75
71	Short-Term Exposure to Tumor Necrosis Factor-Alpha Enables Human Osteoblasts to Direct Adipose Tissue-Derived Mesenchymal Stem Cells into Osteogenic Differentiation. Stem Cells and Development, 2012, 21, 2420-2429.	2.1	68
72	Activation and promotion of adipose stem cells by tumour necrosis factorâ€alpha preconditioning for bone regeneration. Journal of Cellular Physiology, 2013, 228, 1737-1744.	4.1	68

#	Article	IF	Citations
73	The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated. Endocrinology, 2000, 141, 4768-4776.	2.8	68
74	Bone Resorption Caused by Three Periodontal Pathogens In Vivo in Mice Is Mediated in Part by Prostaglandin. Infection and Immunity, 1998, 66, 4158-4162.	2.2	67
75	The role of the bone microenvironment in skeletal metastasis. Journal of Bone Oncology, 2013, 2, 47-57.	2.4	66
76	Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis. Bone, 2010, 47, 795-803.	2.9	65
77	Endogenous glucocorticoid signalling in osteoblasts is necessary to maintain normal bone structure in mice. Bone, 2009, 45, 61-67.	2.9	64
78	RANK ligand. International Journal of Biochemistry and Cell Biology, 2007, 39, 1077-1081.	2.8	63
79	The influence of bone surface availability in bone remodellingâ€"A mathematical model including coupled geometrical and biomechanical regulations of bone cells. Engineering Structures, 2013, 47, 134-147.	5.3	63
80	Osteoprotegerin mitigates tail suspension-induced osteopenia. Bone, 2000, 26, 443-449.	2.9	62
81	Effect of Estrogen versus Testosterone on Circulating Osteoprotegerin and Other Cytokine Levels in Normal Elderly Men. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1550-1554.	3.6	59
82	Prurigo riodularis and aluminium overload in maintenance haemodialysis. Lancet, The, 1992, 340, 48.	13.7	58
83	Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. Bone, 2011, 49, 733-742.	2.9	56
84	Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochemical and Biophysical Research Communications, 2002, 293, 38-44.	2.1	55
85	Accelerated Bone Resorption, Due to Dietary Calcium Deficiency, Promotes Breast Cancer Tumor Growth in Bone. Cancer Research, 2007, 67, 9542-9548.	0.9	55
86	Bone death in hip fracture in the elderly. Calcified Tissue International, 1990, 47, 270-275.	3.1	54
87	Effect of aluminum and parathyroid hormone on osteoblasts and bone mineralization in chronic renal failure. Calcified Tissue International, 1984, 36, 133-138.	3.1	52
88	The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. Clinical and Experimental Metastasis, 2004, 21, 381-387.	3.3	52
89	Unique microstructural design of ceramic scaffolds for bone regeneration under load. Acta Biomaterialia, 2013, 9, 7014-7024.	8.3	51
90	Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Experimental Cell Research, 2004, 293, 292-301.	2.6	50

#	Article	IF	Citations
91	Vitamin D deficiency promotes prostate cancer growth in bone. Prostate, 2011, 71, 1012-1021.	2.3	50
92	Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serumâ€“induced arthritis in vivo. Arthritis and Rheumatism, 2009, 60, 1998-2007.	6.7	49
93	Role of mathematical modeling in bone fracture healing. BoneKEy Reports, 2012, 1, 221.	2.7	49
94	Bone death in transient regional osteoporosis. Bone, 1992, 13, 161-165.	2.9	47
95	Regulation of osteoclast protease expression by RANKL. Biochemical and Biophysical Research Communications, 2003, 310, 774-778.	2.1	47
96	Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Clinical Laboratory, 2006, 52, 1-10.	0.5	47
97	Zirconium Ions Up-Regulate the BMP/SMAD Signaling Pathway and Promote the Proliferation and Differentiation of Human Osteoblasts. PLoS ONE, 2015, 10, e0113426.	2.5	46
98	Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Research, 1997, 57, 3194-9.	0.9	46
99	A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women. Journal of Bone and Mineral Research, 2005, 20, 2274-2282.	2.8	45
100	Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clinical and Experimental Metastasis, 2008, 25, 559-567.	3.3	45
101	Combined treatment with PTH (1â€“34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone, 2005, 37, 87-95.	2.9	44
102	Mathematical modeling of postmenopausal osteoporosis and its treatment by the antiâ€catabolic drug denosumab. International Journal for Numerical Methods in Biomedical Engineering, 2014, 30, 1-27.	2.1	44
103	Loss of the vitamin D receptor in human breast and prostate cancers strongly induces cell apoptosis through downregulation of Wnt/Î²-catenin signaling. Bone Research, 2017, 5, 17023.	11.4	43
104	A Novel Bone Substitute with High Bioactivity, Strength, and Porosity for Repairing Large and Loadâ€Bearing Bone Defects. Advanced Healthcare Materials, 2019, 8, e1801298.	7.6	43
105	Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor ÎºB ligand and MAPK. Biochimica Et Biophysica Acta - Molecular Cell Research, 2004, 1644, 1-7.	4.1	42
106	Sex Steroids, Not FSH, Influence Bone Mass. Cell, 2006, 127, 1079.	28.9	42
107	Fracture behaviors of ceramic tissue scaffolds for load bearing applications. Scientific Reports, 2016, 6, 28816.	3.3	41
108	The Receptor Activator of Nuclear Factor-ÎºB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism. Calcified Tissue International, 2006, 78, 35-44.	3.1	39

#	Article	IF	Citations
109	Sphene ceramics for orthopedic coating applications: An in vitro and in vivo study. Acta Biomaterialia, 2009, 5, 3192-3204.	8.3	38
110	Computational Modeling of Interactions between Multiple Myeloma and the Bone Microenvironment. PLoS ONE, 2011, 6, e27494.	2.5	37
111	The challenge of continuous exogenous glucocorticoid administration in mice. Steroids, 2009, 74, 245-249.	1.8	36
112	Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone. Clinical and Experimental Metastasis, 2014, 31, 921-933.	3.3	36
113	Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. Journal of Cellular Biochemistry, 2002, 86, 642-650.	2.6	35
114	Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2000, 111, 608-617.	2.5	35
115	OPG and PTH-(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats. Endocrinology, 2001, 142, 4295-4304.	2.8	34
116	Quantitative bone histology: A new method. Pathology, 1980, 12, 255-264.	0.6	33
117	A Toxicity Profile of Osteoprotegerin in the Cynomolgus Monkey. International Journal of Toxicology, 2003, 22, 403-412.	1.2	33
118	Direct Crosstalk Between Cancer and Osteoblast Lineage Cells Fuels Metastatic Growth in Bone via Auto-Amplification of IL-6 and RANKL Signaling Pathways. Journal of Bone and Mineral Research, 2014, 29, 1938-1949.	2.8	33
119	Growth retardation and renal osteodystrophy in children with chronic renal failure. Journal of Pediatrics, 1983, 103, 735-740.	1.8	32
120	Bone loss after liver transplantation. Hepatology, 1991, 14, 613-619.	7.3	31
121	Lack of Metabolic Bone Disease in Patients with Fracture of the Femoral Neck*. Australian and New Zealand Journal of Medicine, 1981, 11, 158-161.	0.5	30
122	The effects of osteoprotegerin on the mechanical properties of rat bone. Journal of Materials Science: Materials in Medicine, 2001, 12, 583-588.	3.6	30
123	Efficacy of novel synthetic bone substitutes in the reconstruction of large segmental bone defects in sheep tibiae. Biomedical Materials (Bristol), 2016, 11, 015016.	3.3	30
124	Quantitative Bone Histology in the Hypercalcemia of Malignant Disease*. Journal of Clinical Endocrinology and Metabolism, 1982, 55, 1066-1072.	3.6	29
125	The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women. Osteoporosis International, 1993, 3, 71-75.	3.1	29
126	Baghdadite Ceramics Modulate the Cross Talk Between Human Adipose Stem Cells and Osteoblasts for Bone Regeneration. Tissue Engineering - Part A, 2014, 20, 992-1002.	3.1	29

#	Article	IF	Citations
127	Bone metabolism in idiopathic juvenile osteoporosis: A case report. Calcified Tissue International, 1983, 35, 5-8.	3.1	25
128	The bone remodeling environment is a factor in breast cancer bone metastasis. Bone, 2011, 48, 66-70.	2.9	25
129	High-Strength Fiber-Reinforced Composite Hydrogel Scaffolds as Biosynthetic Tendon Graft Material. ACS Biomaterials Science and Engineering, 2020, 6, 1887-1898.	5.2	25
130	Human amniotic tumor that induces new bone formation in vivo produces growth-regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. Cancer Research, 1996, 56, 633-6.	0.9	25
131	The Effect of Long-Term Low-Dose Diphosphonate Treatment on Rat Bone. Clinical Orthopaedics and Related Research, 1982, &NA;, 290???299.	1.5	24
132	Bone growth is enhanced by novel bioceramic coatings on Ti alloy implants. Journal of Biomedical Materials Research - Part A, 2009, 90A, 419-428.	4.0	24
133	Effects of Materialâ€“Tissue Interactions on Bone Regeneration Outcomes Using Baghdadite Implants in a Large Animal Model. Advanced Healthcare Materials, 2018, 7, e1800218.	7.6	24
134	Quantitative bone histology in children with chronic renal failure. Kidney International, 1982, 21, 833-839.	5.2	23
135	Genetic and hormonal control of bone volume, architecture, and remodeling in XXY mice. Journal of Bone and Mineral Research, 2010, 25, 2148-2154.	2.8	23
136	Osteoprotegerin and Osteoprotegerin Ligand Mediate the Local Regulation of Bone Resorption. , 2000, 10, 18-26.		22
137	The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm. Oncotarget, 2017, 8, 26687-26701.	1.8	22
138	PATHOLOGIC FRACTURE DUE TO SEVERE OSTEOMALACIA FOLLOWING LOWâ€ĐOSE DIPHOSPHONATE TREATMENT OF PAGET'S DISEASE OF BONE. Australian and New Zealand Journal of Medicine, 1983, 13, 277-279.	0.5	21
139	Personalized Baghdadite scaffolds: stereolithography, mechanics and in vivo testing. Acta Biomaterialia, 2021, 132, 217-226.	8.3	21
140	Fibroblast Growth Factor 23: A Phosphatonin Regulating Phosphate Homeostasis?. Endocrinology, 2004, 145, 3084-3086.	2.8	20
141	Hypothesis: Bones Toughness Arises from the Suppression of Elastic Waves. Scientific Reports, 2014, 4, 7538.	3.3	20
142	Nanoemulsion-Enabled Oral Delivery of Novel Anticancer Ï‰-3 Fatty Acid Derivatives. Nanomaterials, 2018, 8, 825.	4.1	20
143	Review: Photochemical Tissue Bonding (PTB) methods for sutureless tissue adhesion. International Journal of Adhesion and Adhesives, 2016, 71, 87-98.	2.9	18
144	Burning daylight: balancing vitamin D requirements with sensible sun exposure. Medical Journal of Australia, 2011, 194, 345-348.	1.7	17

#	Article	IF	Citations
145	A Novel Arylurea Fatty Acid That Targets the Mitochondrion and Depletes Cardiolipin To Promote Killing of Breast Cancer Cells. Journal of Medicinal Chemistry, 2017, 60, 8661-8666.	6.4	17
146	Reprogramming of human fibroblasts into osteoblasts by insulin-like growth factor-binding protein 7. Stem Cells Translational Medicine, 2020, 9, 403-415.	3.3	17
147	Characterization of osteoclast precursors in human blood. British Journal of Haematology, 2000, 111, 501-512.	2.5	15
148	Osteoprotegerin ameliorates sciatic nerve crush induced bone loss. Journal of Orthopaedic Research, 2001, 19, 518-523.	2.3	15
149	Fabrication of a novel triphasic and bioactive ceramic and evaluation of its in vitro and in vivo cytocompatibility and osteogenesis. Journal of Materials Chemistry B, 2014, 2, 1866.	5.8	15
150	Measurement of bone in the os calcis: A clinical evaluation. Journal of Bone and Mineral Research, 1989, 4, 507-514.	2.8	13
151	CXCL12/CXCR4 Axis in Tissue Targeting and Bone Destruction in Cancer and Multiple Myeloma. Journal of Bone and Mineral Research, 2009, 24, 1147-1149.	2.8	13
152	Osteoblast-targeted disruption of glucocorticoid signalling does not delay intramembranous bone healing. Steroids, 2010, 75, 282-286.	1.8	13
153	Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer. Cancer Research, 1995, 55, 1989-93.	0.9	12
154	The 18 kDa Translocator Protein (Peripheral Benzodiazepine Receptor) Expression in the Bone of Normal, Osteoprotegerin or Low Calcium Diet Treated Mice. PLoS ONE, 2012, 7, e30623.	2.5	11
155	Bone Resorption Caused by Three Periodontal Pathogens In Vivo in Mice Is Mediated in Part by Prostaglandin. Infection and Immunity, 1998, 66, 4158-4162.	2.2	11
156	Effects of Human Tumor Cell Lines on Local New Bone Formation In Vivo. Calcified Tissue International, 1997, 60, 210-215.	3.1	10
157	Activation of the pro-migratory bone morphogenetic protein receptor 1B gene in human MDA-MB-468 triple-negative breast cancer cells that over-express CYP2J2. International Journal of Biochemistry and Cell Biology, 2016, 80, 173-178.	2.8	10
158	Baghdadite Ceramics Prevent Senescence in Human Osteoblasts and Promote Bone Regeneration in Aged Rats. ACS Biomaterials Science and Engineering, 2020, 6, 6874-6885.	5.2	10
159	Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide. Clinical and Experimental Metastasis, 1998, 16, 645-654.	3.3	9
160	Characterisation of a novel light activated adhesive scaffold: Potential for device attachment. Journal of the Mechanical Behavior of Biomedical Materials, 2016, 62, 433-445.	3.1	8
161	Histomorphological and torque removal comparison of 6 mm orthodontic miniscrews with and without surface treatment in New Zealand rabbits. European Journal of Orthodontics, 2015, 37, 578-583.	2.4	7
162	Adult osteosclerosis. Metabolic Bone Disease & Related Research, 1983, 5, 111-117.	0.5	6

#	Article	IF	Citations
163	Limitations of bone biopsy. Bone, 1985, 6, 401-401.	2.9	6
164	The effectiveness of a soluble calcium preparation as a gut phosphate binder. Metabolism: Clinical and Experimental, 1988, 37, 815-819.	3.4	6
165	Bone Balance within a Cortical BMU: Local Controls of Bone Resorption and Formation. PLoS ONE, 2012, 7, e40268.	2.5	6
166	Treatment of Paget's disease of bone with a combination of intranasal salmon calcitonin and oral calcium and thiazide. Calcified Tissue International, 1991, 49, 164-167.	3.1	5
167	The aryl-ureido fatty acid CTU activates endoplasmic reticulum stress and PERK/NOXA-mediated apoptosis in tumor cells by a dual mitochondrial-targeting mechanism. Cancer Letters, 2022, 526, 131-141.	7.2	5
168	Measurement of osteoclasts and bone resorption by automated image analysis. Journal of Bone and Mineral Research, 1993, 8, 139-145.	2.8	4
169	Functional Ultra-High Molecular Weight Polyethylene Composites for Ligament Reconstructions and Their Targeted Applications in the Restoration of the Anterior Cruciate Ligament. Polymers, 2022, 14, 2189.	4.5	4
170	Mitogenic Lectin Concanavalin A Induces Calvarial Bone Formation In Vivo via Indomethacin-Sensitive Pathway. Calcified Tissue International, 1997, 60, 204-209.	3.1	3
171	A comparative histomorphological and micro computed tomography study of the primary stability and the osseointegration of The Sydney Mini Screw; a qualitative pilot animal study in New Zealand rabbits. European Journal of Orthodontics, 2019, 41, 360-369.	2.4	3
172	The Pathogenesis of Renal Osteodystrophy: Role of Vitamin D, Aluminium, Parathyroid Hormone, Calcium and Phosphorus. QJM - Monthly Journal of the Association of Physicians, 0, , .	0.5	2
173	Computer Simulation-Based Modeling of the Pharmaceutical Intervention of Postmenopausal Osteoporosis by Denosumab. , 2012, , .		2
174	Mechanisms of Disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nature Clinical Practice Oncology, 2006, 3, E1-E1.	4.3	2
175	Design and evaluation of 3D-printed Sr-HT-Gahnite bioceramic for FDA regulatory submission: A Good Laboratory Practice sheep study. Acta Biomaterialia, 2023, 156, 214-221.	8.3	2
176	Letters to the Editor. Journal of Bone and Mineral Research, 1990, 5, 419-420.	2.8	1
177	Aluminium-related Bone Disease Presenting with Calcaneal Stress Fractures. Rheumatology, 1993, 32, 260-261.	1.9	1
178	Theoretical analysis of the spatio-temporal structure of bone multicellular units. IOP Conference Series: Materials Science and Engineering, 2010, 10, 012132.	0.6	1
179	Wnt7b plays a unique and essential role in osteoblast differentiation. Bone, 2010, 47, S370.	2.9	1
180	Vitamin D supplements and bone mineral density. Lancet, The, 2014, 383, 1292.	13.7	1

#	Article	IF	Citations
181	A Toxicity Profile of Osteoprotegerin in the Cynomolgus Monkey. International Journal of Toxicology, 2003, 22, 403-412.	1.2	1
182	The Role of RANK, RANK Ligand and Osteoprotegerin in the Lytic Effects and Growth of Bone Metastases. , 2006, , 51-62.		0
183	New insights into therapeutic drug interventions for catabolic bone diseases using an in-silico modeling approach. Bone, 2009, 44, S135-S136.	2.9	0
184	PTU, a novel ureido-fatty acid, inhibits MDA-MB-231 cell invasion and dissemination by modulating Wnt5a secretion and cytoskeletal signaling. Biochemical Pharmacology, 2021, 192, 114726.	4.4	0